General
Preferred name
MERCAPTOPURINE
Synonyms
6-Mercaptopurine ()
6-MP ()
6-Mercaptopurine monohydrate ()
6-Mercaptopurine (6-MP) Monohydrate ()
MERCAPTOPURINE ANHYDROUS ()
6-Mercaptopurine hydrate ()
MERCAPTOPURINE HYDRATE ()
6-MP hydrate ()
Mercaptopurine (6-MP) ()
Mercaptopurine6-Purinethiol6-Mercaptopurine6-ThiopurinePurinethol6-MP3H-Purine-6-thiolPurine, 6-mercapto-7-Mercapto-1,3,4,6-tetrazaindeneIsmipur ()
6-Mercaptopurine (hydrate) ()
Xaluprine ()
Mercaptopurinum ()
Purinethol ()
Mercaptopurina ()
6-mercaptopurine monohydrate ()
NSC-759614 ()
Puri-Nethol ()
Purixan ()
NSC-755 ()
Mercaptopurine hydrate ()
Xaluprine (previously mercaptopurine nova laboratories) ()
Mercaptopurine ()
P&D ID
PD001869
CAS
6112-76-1
50-44-2
1194-62-3
Tags
available
drug
nuisance
Approved by
FDA
First approval
1953
Drug indication
Acute lymphoblastic leukaemia
Middle East Respiratory Syndrome (MERS)
Crohn disease
Severe acute respiratory syndrome (SARS)
Crohn's disease
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
Mercaptopurine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to thioinosinic acid (TIMP). TIMP inhibits several reactions that involve inosinic acid (IMP), such as the conversion of IMP to xanthylic acid (XMP) and the conversion of IMP to adenylic acid (AMP) via adenylosuccinate (SAMP). Upon methylation, TIMP forms 6-methylthioinosinate (MTIMP) which inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase in addition to TIMP. Glutamine-5-phosphoribosylpyrophosphate amidotransferase is the first enzyme unique to the _de novo_ pathway for purine ribonucleotide synthesis. According to experimental findings using radiolabeled mercaptopurine, mercaptopurine may be recovered from the DNA in the form of deoxythioguanosine. In comparison, some mercaptopurine may be converted to nucleotide derivatives of 6-thioguanine (6-TG) via actions of inosinate (IMP) dehydrogenase and xanthylate (XMP) aminase that convert TIMP to thioguanylic acid (TGMP).
DESCRIPTION
Mercaptopurine has immunosuppressive action as well as antineoplastic activity.
(GtoPdb)
DESCRIPTION
6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.
PRICE
29
DESCRIPTION
6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.
PRICE
29
DESCRIPTION
Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Mercaptopurine is an antimetabolite antineoplastic agent with immunosuppressant properties. It is indicated for remission induction and maintenance therapy of acute lymphatic leukemia.
(Enamine Bioactive Compounds)
DESCRIPTION
6-Mercaptopurine (6-MP) is an antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
(TargetMol Bioactive Compound Library)
DESCRIPTION
6-Mercaptopurine hydrate (6-Mercaptopurine monohydrate) is a Nucleoside Metabolic Inhibitor. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
24
Organisms
1
Compound Sets
32
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NIH Clinical Collections (NCC)
NIH Mechanistic Set
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
99
Molecular Weight
152.02
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
0
Ring Count
2
Aromatic Ring Count
2
cLogP
1.02
TPSA
57.36
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
1
Nonspecific reactivity
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
MOA
ribonucleoside-diphosphate reductase inhibitor
Immunosuppressive
Purine Antagonists
immunosuppressant, protein synthesis inhibitor, purine antagonist
Target
DNA
Amidophosphoribosyltransferase
DNA synthesis
Nucleoside antimetabolite/analog
PRPP Amidotransferase
HPRT1, IMPDH1, IMPDH2, PPAT
Purine analog
Endogenous Metabolite
DNA/RNA Synthesis
HPRT
IMPDH
Pathway
Autophagy
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Metabolism
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Member status
member
Indication
acute lymphoblastic leukemia (ALL)
Therapeutic Class
Anticancer Agents
Antiviral Agents
Source data
